Skip to main content

Table 3 Selected heterologous booster studies on mix and match approach

From: COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

A

COV-BOOST Trial—Munro et al., 2021 (UK) [165]

Primary doses

N = 2557

anti-spike IgG, ELU/mL

Pseudovirus neutralizing antibody (GMT) Delta NT50

Live virus neutralizing antibody NT80

Cellular response WT

Cellular response, Delta

ChAd/ChAd

–

93

801

20.0

146

48.1

38.1

ChAd/ChAd

ChAd

100

2457

48.9

346

53.0

44.9

ChAd/ChAd

NVX

96

6975

124

837

113.7

117.9

ChAd/ChAd

NVX (half)

97

4634

87.2

713

98.4

86.3

ChAd/ChAd

–

93

763

20.4

174

42.6

42.2

ChAd/ChAd

BNT

95

20,517

315

4899

115.5

123.2

ChAd/ChAd

VLA

95

1835

35.2

354

52.2

123.2

ChAd/ChAd

VLA (half)

107

1430

31.1

301

55.5

54.7

ChAd/ChAd

Ad26

101

5517

125

1053

106.0

102.1

ChAd/ChAd

–

102

852

18.6

152

39.5

35.2

ChAd/ChAd

BNT (half)

105

16,045

321.3

2501

135.9

139.1

ChAd/ChAd

mRNA

98

31,111

559.7

5421

148.9

152.1

ChAd/ChAd

CVnCoV

105

3996

64.5

774

47.8

45.5

BNT/BNT

-

111

2541

37.9

531

34.5

35.7

BNT/BNT

ChAd

98

13,424

260

2614

95.8

108.0

BNT/BNT

NVX

103

10,862

165

1454

56.6

56.9

BNT/BNT

NVX

99

8550

131

1792

35.3

41.6

BNT/BNT

–

97

3197

56.5

756

29.4

28.2

BNT/BNT

BNT

96

27,242

392

4603

83.8

82.1

BNT/BNT

VLA

99

4204

67.1

836

33.5

29.6

BNT/BNT

VLA (half)

98

3721

54.7

555

38.1

39.2

BNT/BNT

Ad26

89

17,079

418

3535

111.0

121.5

BNT/BNT

–

100

3029

41.6

469

22.0

25.9

BNT/BNT

BNT (half)

94

23,082

352.6

3263

78.4

93.0

BNT/BNT

mRNA

92

33,768

508.7

5354

112.0

118.3

BNT/BNT

CVnCoV

94

7613

119.1

1960

46.7

52.2

B

MixNMatch Trial—Atmar et al., 2022 (US) [167]

Primary doses

N = 458

IgG serum binding antibody titer (GMT)

Th1 CD4 + T cell, Median %

Th2 CD4 + T cell, Median %

Th1 CD8 + T cell, Median %

BNT/BNT

BNT

50

3164

0.11 >  > 0.21

0.00 >  > 0.02

0.03 >  > 0.11

BNT/BNT

mRNA

51

5231

0.14 >  > 0.32

0.00 >  > 0.01

0.02 >  > 0.08

BNT/BNT

Ad26

53

2600

0.11 >  > 0.18

0.00 >  > 0.00

0.06 >  > 0.13

mRNA/mRNA

BNT

50

5273

0.26 >  > 0.33

0.01 >  > 0.03

0.02 >  > 0.08

mRNA/mRNA

mRNA

51

6224

0.24 >  > 0.48

0.00 >  > 0.03

0.02 >  > 0.06

mRNA/mRNA

Ad26

53

4560

0.34 >  > 0.39

0.03 >  > 0.02

0.03 >  > 0.11

Ad26

BNT

51

2277

0.06 >  > 0.21

0.00 >  > 0.01

0.17 >  > 0.83

Ad26

mRNA

49

2986

0.13 >  > 0.26

0.00 >  > 0.00

0.32 >  > 0.66

Ad26

Ad26

50

369

0.10 >  > 0.09

0.00 >  > 0.00

0.19 >  > 0.15

   

* Day 29

* Day 1 >  > Day 15 after booster

C

Costa Clemens et al., 2022 (Brazil) [166]

Primary doses

N = 1240

Anti-spike igG

Pseudovirus neutralisation titres (GMR)

CoronaVac/CoronaVac

Ad26

294

6.7

8.7

CoronaVac/CoronaVac

BNT

333

13.4

21.5

CoronaVac/CoronaVac

ChAd

296

7.0

10.6

CoronaVac/CoronaVac

CoronaVac

281

1 (ref)

1 (ref)

  1. BNT: BNT162b2; mRNA: mRNA-1273; ChAdOx1: ChAd; Ad26: Ad26.COV2.S; NVX: NVX-CoV2373; VLA: VLA2001; –: control (3 control groups in total in the trial)
  2. * Calculate as spots per 1 M PBMC